Narcolepsy Therapeutics Market Projected to Reach USD 7,852.93 Million by 2034, Growing at a CAGR of 7.5%

The narcolepsy therapeutics market was valued at USD 3,819.10 million in 2024. It is expected to reach USD 7,852.93 million by 2034, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2034.

Market Preface
Narcolepsy is a condition that increases the sleepiness in people during the day and can cause them to fall asleep instantly. Some people also encounter other symptoms, such as muscle fragility, when they discern robust emotions. The healthcare provider may conjecture narcolepsy depending on the indications of excessive daytime sleeping and instant loss of muscle tone, known as cataplexy. The healthcare expert might suggest a sleep specialist.

Medicines that energize the central nervous system are the prominent cures to assist people with narcolepsy to stay awake in the course of the day. The healthcare expert may suggest modafinil or armodafinil. These medicines are not habit-configured as older stimulants. There are certain home remedies that one can follow, such as sticking to a schedule, such as going to sleep and waking up at allotted times, even during weekends.

Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/global-narcolepsy-therapeutics-market/request-for-sample

Competitive Landscape
The market is aggressive in nature with several extensive multinationals and small and moderate sized firms. Some of the current players in the market are:

• Addrenex Pharmaceuticals, Inc.
• Arena Pharmaceuticals, Inc.
• Avadel Pharmaceuticals plc
• Axsome Therapeutics, Inc.
• BIOPROJET
• Graymark Healthcare, Inc.
• Harmony Biosciences Holdings, Inc.
• Janssen Global Services, LLC
• Jazz Pharmaceuticals plc
• NLS Pharmaceutics Ltd.
• Novartis AG

Narcolepsy Therapeutics Market Report Highlights
• Based on treatment, the narcolepsy with cataplexy segment dominated the narcolepsy therapeutics market share in 2024 due to the high prevalence of cataplexy among narcolepsy patients and the availability of effective treatments such as sodium oxybate. However, the narcolepsy without cataplexy segment is growing steadily as treatments for excessive daytime sleepiness gain traction.

• In terms of product, the sodium oxybate segment dominated the narcolepsy therapeutics market revenue in 2024, owing to its proven efficacy in treating both cataplexy and excessive daytime sleepiness in narcolepsy patients. The central nervous system stimulants segment is showing strong growth as a primary treatment for managing sleepiness.

• North America held the major market share in 2024 due to advanced healthcare infrastructure and high awareness levels. However, Asia Pacific is the fastest-growing region, fueled by improving healthcare access and rising awareness of narcolepsy.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/global-narcolepsy-therapeutics-market/request-for-discount-pricing

Growth Drivers
Growing Consciousness: The identification and awareness of narcolepsy have enhanced lately, resulting in market growth. Research signifies that narcolepsy impacts roughly 37.7 of 100,000 persons in the US, paralleling approximately 126191 people nationwide. Growing consciousness in context to the condition has caused more individuals to adopt suitable treatments, thus propelling the narcolepsy therapeutics market forward.

Sizeable Progressions in Pharmacological Mediation: Notable advancements in pharmacological mediation have pushed the market demand. Current advancements involve the acceptance of medicines such as pitolisant and solriamfetol, which provide contemporary alternatives for handling immoderate daytime sleepiness and cataplexy. Further, continuing research into new treatment perspectives, such as orexin receptor agonists, targets to confront the fundamental causes of narcolepsy, essentially providing more productive and earmarked therapies in the time to come.

Market Segmentation
The narcolepsy therapeutics market segmentation is done on the basis of treatment, product, and region.
By treatment analysis, the narcolepsy with cataplexy segment holds the largest market share in 2024 due to the growing existence of cataplexy amongst narcoleptic patients.
By product analysis, the sodium oxybate segment dominated the market in 2024 due to elevated prescription rates, approving repayment schemes, and growing consciousness of narcolepsy treatments.

Global Narcolepsy Therapeutics Market, by Treatment
5.1. Key Findings
5.2. Introduction
5.2.1. Global Narcolepsy Therapeutics Market, by Treatment, 2020-2034 (USD Million)
5.3. Narcolepsy With Cataplexy
5.3.1. Global Narcolepsy Therapeutics Market, by Narcolepsy With Cataplexy, by Region, 2020-2034 (USD Million)
5.4. Narcolepsy Without Cataplexy
5.4.1. Global Narcolepsy Therapeutics Market, by Narcolepsy Without Cataplexy, by Region, 2020-2034 (USD Million)
5.5. Secondary Narcolepsy
5.5.1. Global Narcolepsy Therapeutics Market, by Secondary Narcolepsy, by Region, 2020-2034 (USD Million)

Global Narcolepsy Therapeutics Market, by Product
6.1. Key Findings
6.2. Introduction
6.2.1. Global Narcolepsy Therapeutics Market, by Product, 2020-2034 (USD Million)
6.3. Central Nervous System Stimulants
6.3.1. Global Narcolepsy Therapeutics Market, by Central Nervous System Stimulants, by Region, 2020-2034 (USD Million)
6.4. Sodium Oxybate
6.4.1. Global Narcolepsy Therapeutics Market, by Sodium Oxybate, by Region, 2020-2034 (USD Million)
6.5. Selective Serotonin Reuptake Inhibitor
6.5.1. Global Narcolepsy Therapeutics Market, by Selective Serotonin Reuptake Inhibitor, by Region, 2020-2034 (USD Million)
6.6. Tricyclic Antidepressants
6.6.1. Global Narcolepsy Therapeutics Market, by Tricyclic Antidepressants, by Region, 2020-2034 (USD Million)
6.7. Others
6.7.1. Global Narcolepsy Therapeutics Market, by Others, by Region, 2020-2034 (USD Million)

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/global-narcolepsy-therapeutics-market

Regional Analysis
• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

More Trending Latest Reports by Polaris Market Research:
Medical Devices Market
https://www.polarismarketresearch.com/industry-analysis/medical-devices-market

Placenta Market
https://www.polarismarketresearch.com/industry-analysis/placenta-market

Soft Tissue Sarcoma Treatment Market
https://www.polarismarketresearch.com/industry-analysis/soft-tissue-sarcoma-treatment-market

Neurothrombectomy Devices Market
https://www.polarismarketresearch.com/industry-analysis/neurothrombectomy-devices-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.